Hypothesis Comparison

⚛ Collide these ⚔ Judge as Duel

Comparing 2 hypotheses side-by-side

|

RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

TARDBP · neurodegeneration · therapeutic
Composite
0.465
Price
$0.46
Evidence For
0
Evidence Against
0

Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.

STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Function Marker of TDP-43 N

TARDBP · ALS · mechanistic
Composite
0.702
Price
$0.50
Evidence For
0
Evidence Against
0

Loss of nuclear TDP-43 in ALS motor neurons first manifests as aberrant inclusion of the STMN2 cryptic exon 2a, producing a truncated non-functional STMN2 protein that impairs microtubule repair at the axon. This splicing defect precedes detectable cytoplasmic TDP-43 aggregation by at least 48h in iPSC motor neurons subjected to TDP-43 depletion, establishing STMN2 cryptic exon inclusion as the earliest measurable loss-of-function event. Restoring STMN2 function with antisense oligonucleotides s

Convergent vs Divergent Predictions

This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.

TARDBPRna Splicing / Axon BiologyProtein Aggregation
Convergent signals
  • TARDBP recurs across 2 selected hypotheses with aligned directionality in RNA splicing / axon biology, protein aggregation.
Divergent signals
  • No direct polarity conflicts detected among the selected hypotheses.

Verdict Summary

7/11
dimensions won
RNA-Binding Competition Therapy for TDP-
4/11
dimensions won
STMN2 Cryptic Exon Inclusion is the Earl

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.50
0.94
Evidence
0.40
0.60
Novelty
0.85
0.55
Feasibility
0.25
0.75
Impact
0.45
0.88
Druggability
0.30
0.00
Safety
0.25
0.00
Competition
0.75
0.00
Data
0.35
0.00
Reproducible
0.30
0.00
KG Connect
0.79
0.50

Score Breakdown

DimensionRNA-Binding Competition TherapSTMN2 Cryptic Exon Inclusion i
Mechanistic0.5000.940
Evidence0.4000.600
Novelty0.8500.550
Feasibility0.2500.750
Impact0.4500.880
Druggability0.3000.000
Safety0.2500.000
Competition0.7500.000
Data0.3500.000
Reproducible0.3000.000
KG Connect0.7880.500

Evidence

RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

No evidence citations yet

STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Functio

No evidence citations yet

Debate Excerpts

RNA-Binding Competition Therapy for TDP-43 Cross-S

4 rounds · quality: 0.95

Theorist

# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...

Theorist

# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...

Skeptic

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...

Skeptic

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...

STMN2 Cryptic Exon Inclusion is the Earliest Loss-

4 rounds · quality: 0.67

Theorist

Theorist position for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons Source basis: Molecular Mechanisms of ...

Skeptic

Skeptic critique for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons The source paper motivates the gap, but...

Domain Expert

Domain expert assessment for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons The practical path is feasible ...

Synthesizer

{ "ranked_hypotheses": [ { "title": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Causal Sequence of TDP-43 ...

Price History Overlay

Knowledge Graph Comparison

RNA-Binding Competition Therapy for TDP-

61 edges
Top Node Types
protein38
gene9
process7
pathway5
cell_type2
Top Relations
associated_with11
promotes8
recruits6
encodes5
localizes_to5

STMN2 Cryptic Exon Inclusion is the Earl

0 edges
Top Node Types
Top Relations

Pathway Diagrams

Curated mechanism pathway diagrams from expert analysis

RNA-Binding Competition Therapy for TDP-43 Cross-S

graph TD
    A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
    B --> C["Splicing Regulation"]
    B --> D["RNA Transport"]
    B --> E["RNA Stability"]

    F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
    G --> H["Hyperphosphorylation"]
    H --> I["TDP-43 Aggregation"]
    I --> J["Cross-Seeding with Other Proteins"]
    J --> K["ALS/FTD Pathology"]

    L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
    M --> N["Compete for TDP-43 RNA-Binding Domain"]
    N --> O["Sequester TDP-43 in Soluble Form"]

    O --> P["Prevent Cytoplasmic Aggregation"]
    O --> Q["Block Cross-Seeding"]
    O --> R["Preserve Some RNA Processing"]

    P --> S["Reduced TDP-43 Inclusions"]
    Q --> T["Prevented Prion-like Spread"]
    R --> U["Maintained Cellular Function"]

    S --> V["Neuroprotection in ALS/FTD"]
    T --> V
    U --> V

    style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
    style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
    style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
    style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0